BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 18081660)

  • 1. Review article: Success and failure of nucleoside and nucleotide analogues in chronic hepatitis B.
    Leemans WF; Ter Borg MJ; de Man RA
    Aliment Pharmacol Ther; 2007 Dec; 26 Suppl 2():171-82. PubMed ID: 18081660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
    Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
    J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
    Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
    Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Commentary: combination therapy with two nucleos(t)ide analogues in chronic hepatitis B.
    Hadziyannis SJ
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1482. PubMed ID: 22582839
    [No Abstract]   [Full Text] [Related]  

  • 5. Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice.
    Lampertico P
    J Hepatol; 2009 Apr; 50(4):644-7. PubMed ID: 19231017
    [No Abstract]   [Full Text] [Related]  

  • 6. Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success.
    Chien RN; Liaw YF
    Best Pract Res Clin Gastroenterol; 2008; 22(6):1081-92. PubMed ID: 19187868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic hepatitis B--treatment with nucleoside analogues.
    Leung N
    Med J Malaysia; 2005 Jul; 60 Suppl B():22-7. PubMed ID: 16108169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues.
    Lampertico P; Colombo M
    Liver Int; 2009 Jan; 29 Suppl 1():130-2. PubMed ID: 19207976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
    Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective.
    Chien RN
    J Gastroenterol Hepatol; 2010 May; 25(5):852-7. PubMed ID: 20546437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides.
    Nguyen MH; Keeffe EB
    J Viral Hepat; 2009 Mar; 16(3):149-55. PubMed ID: 19236641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
    Dakin H; Fidler C; Harper C
    Value Health; 2010 Dec; 13(8):934-45. PubMed ID: 20825624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Redetection of HBV lamivudine-resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analogues.
    Rodriguez-Frias F; Jardi R; Schaper M; Gimferrer M; Elefsiniotis I; Tabernero D; Esteban R; Buti M
    J Med Virol; 2007 Nov; 79(11):1671-3. PubMed ID: 17854030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of tenofovir in a kidney transplant patient with chronic hepatitis B and nucleos(t)ide multidrug resistance: a case report.
    Shan C; Yin GQ; Wu P
    J Med Case Rep; 2014 Aug; 8():281. PubMed ID: 25146249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression?
    Buster EH; Janssen HL
    Neth J Med; 2006 Jun; 64(6):175-85. PubMed ID: 16788215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
    Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
    Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs.
    Petersen J; Buti M
    Expert Rev Gastroenterol Hepatol; 2012 Dec; 6(6):683-93; quiz 694. PubMed ID: 23237254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current therapy with nucleoside/nucleotide analogs for patients with chronic hepatitis B.
    Xu XW; Chen YG
    Hepatobiliary Pancreat Dis Int; 2006 Aug; 5(3):350-9. PubMed ID: 16911930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment.
    Moriconi F; Colombatto P; Coco B; Ciccorossi P; Oliveri F; Flichman D; Maina AM; Sacco R; Bonino F; Brunetto MR
    J Antimicrob Chemother; 2007 Aug; 60(2):341-9. PubMed ID: 17567633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral options for the treatment of chronic hepatitis B.
    Osborn MK; Lok AS
    J Antimicrob Chemother; 2006 Jun; 57(6):1030-4. PubMed ID: 16595637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.